Cargando…

Combination treatment including targeted therapy for advanced hepatocellular carcinoma

Management of advanced hepatocellular carcinoma (HCC), one of the most lethal cancers worldwide, has presented a therapeutic challenge over past decades. Most patients with advanced HCC and a low possibility of surgical resection have limited treatment options and no alternative but to accept local...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jianzhen, Wu, Liangcai, Bai, Xue, Xie, Yuan, Wang, Anqiang, Zhang, Haohai, Yang, Xiaobo, Wan, Xueshuai, Lu, Xin, Sang, Xinting, Zhao, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342607/ https://www.ncbi.nlm.nih.gov/pubmed/27626176 http://dx.doi.org/10.18632/oncotarget.11954

Ejemplares similares

Brain metastases from hepatocellular carcinoma: recent advances and future avenues
por: Wang, Shanshan, et al.
Publicado: (2017)

Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma
por: Zhang, Haohai, et al.
Publicado: (2015)

Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing
por: Zheng, Yongchang, et al.
Publicado: (2017)

Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct
por: Wan, Xueshuai, et al.
Publicado: (2017)

Coffee and cancer risk: A meta-analysis of prospective observational studies
por: Wang, Anqiang, et al.
Publicado: (2016)

Long Noncoding RNA Plays a Key Role in Metastasis and Prognosis of Hepatocellular Carcinoma
por: Li, Guangbing, et al.
Publicado: (2014)

Citrus Fruit Intake Substantially Reduces the Risk of Esophageal Cancer: A Meta-Analysis of Epidemiologic Studies
por: Wang, Anqiang, et al.
Publicado: (2015)

The fusion landscape of hepatocellular carcinoma
por: Zhu, Chengpei, et al.
Publicado: (2019)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Clinicopathological Features of Gallbladder Papillary Adenocarcinoma
por: Wan, Xueshuai, et al.
Publicado: (2014)

Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing
por: Yang, Xiaobo, et al.
Publicado: (2014)

A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2018)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians
por: Deng, Kaige, et al.
Publicado: (2023)

Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma
por: Wang, Anqiang, et al.
Publicado: (2018)

Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Mutational spectrum and precision oncology for biliary tract carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis
por: Bian, Jin, et al.
Publicado: (2017)

Tea consumption and the risk of biliary tract cancer: a systematic review and dose–response meta-analysis of observational studies
por: Xiong, Jianping, et al.
Publicado: (2017)

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
por: Wang, Dongxu, et al.
Publicado: (2020)

The diagnostic and prognostic role of RhoA in hepatocellular carcinoma
por: Bai, Yi, et al.
Publicado: (2019)

N6-methyladenosine associated prognostic model in hepatocellular carcinoma
por: Huang, Hanchun, et al.
Publicado: (2020)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma
por: Huang, Hanchun, et al.
Publicado: (2019)

A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling
por: Wu, Liangcai, et al.
Publicado: (2016)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
por: Long, Junyu, et al.
Publicado: (2021)

Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma
por: Bian, Jin, et al.
Publicado: (2021)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
por: Long, Junyu, et al.
Publicado: (2022)

Application and Progress of Cultured Models of Gallbladder Carcinoma
por: Xing, Jiali, et al.
Publicado: (2023)

Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Perioperative management of patients with liver cancer complicated with sarcopenia
por: Xing, Jiali, et al.
Publicado: (2022)

Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma
por: Wang, Yuxin, et al.
Publicado: (2023)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma
por: Zuo, Bangyou, et al.
Publicado: (2022)

Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival
por: Lin, Jianzhen, et al.
Publicado: (2019)

Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
por: Zhang, Junwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7shcoamd9oqth3kroprsbck7ls